Regeneron Pharmaceuticals Inc (REGN)

Return on total capital

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 3,956,100 4,131,800 4,080,900 4,113,100 4,272,300 4,448,500 4,845,000 4,719,500 4,918,200 6,093,600 6,399,300 9,190,200 9,383,100 8,105,000 7,298,800 4,460,200 3,867,300 3,524,400 3,276,100 2,580,200
Long-term debt US$ in thousands 1,984,400 1,984,000 1,983,600 1,983,300 1,982,900 1,982,600 1,982,200 1,981,800 1,981,400 1,981,100 1,980,700 1,980,400 1,980,000 1,979,600 1,979,200 1,978,900 1,978,500 1,978,300 — —
Total stockholders’ equity US$ in thousands 29,353,600 29,325,900 28,205,800 26,991,100 25,973,100 24,904,400 24,017,900 23,495,200 22,664,000 21,438,800 20,687,800 19,914,700 18,768,800 17,258,000 15,127,300 11,977,000 11,025,300 10,125,500 9,057,400 12,133,000
Return on total capital 12.62% 13.20% 13.52% 14.20% 15.28% 16.55% 18.63% 18.52% 19.96% 26.02% 28.23% 41.97% 45.22% 42.13% 42.67% 31.96% 29.74% 29.12% 36.17% 21.27%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $3,956,100K ÷ ($1,984,400K + $29,353,600K)
= 12.62%

Regeneron Pharmaceuticals Inc's return on total capital has exhibited some fluctuations over the observed period. The ratio ranged from a high of 45.22% at the end of December 2021 to a low of 12.62% at the end of December 2024. The company experienced a peak in performance in mid-2021, with return on total capital reaching levels above 40%. However, this trend reversed in the following periods, showing a decline in the ratio thereafter. It is important for stakeholders to monitor the company's return on total capital closely to assess its efficiency in generating returns from the total capital employed in its operations.